KaloBios to Present at Leerink Swann Rare Disease Roundtable

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Leerink Swann Rare Disease Roundtable on October 2 at the Le Parker Meridien in New York City. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Company Presentation:
When: Wednesday, October 2, 2013, 10:30 AM EDT
Where: Le Parker Meridien, New York City, NY

Webcast:
To access the live and archived audio webcast of this presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab: http://leerink.metameetings.com/webcasts/rdroundtable13/directlink?ticker=KBIO.

A replay of the webcast will be available one hour after the conclusion of the live event. 

About KaloBios
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer.  For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

Contact:

Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
ir@kalobios.com

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates 
Tel:  (415) 821-2413
Mobile: (415) 690-0210
Joan@Kureczka-Martin.com

SOURCE KaloBios Pharmaceuticals



RELATED LINKS
http://www.kalobios.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.